» Articles » PMID: 35444359

Network-based Survival Analysis to Discover Target Genes for Developing Cancer Immunotherapies and Predicting Patient Survival

Overview
Journal J Appl Stat
Specialty Public Health
Date 2022 Apr 21
PMID 35444359
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, cancer immunotherapies have been life-savers, however, only a fraction of treated patients have durable responses. Consequently, statistical methods that enable the discovery of target genes for developing new treatments and predicting patient survival are of importance. This paper introduced a network-based survival analysis method and applied it to identify candidate genes as possible targets for developing new treatments. RNA-seq data from a mouse study was used to select differentially expressed genes, which were then translated to those in humans. We constructed a gene network and identified gene clusters using a training set of 310 human gliomas. Then we conducted gene set enrichment analysis to select the gene clusters with significant biological function. A penalized Cox model was built to identify a small set of candidate genes to predict survival. An independent set of 690 human glioma samples was used to evaluate predictive accuracy of the survival model. The areas under time-dependent ROC curves in both the training and validation sets are more than 90%, indicating strong association between selected genes and patient survival. Consequently, potential biomedical interventions targeting these genes might be able to alter their expressions and prolong patient survival.

Citing Articles

Integrated partially linear model for multi-center studies with heterogeneity and batch effect in covariates.

Yang L, Shao Y Statistics (Ber). 2024; 57(5):987-1009.

PMID: 38283617 PMC: 10812905. DOI: 10.1080/02331888.2023.2258429.


Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.

Lu Y, Shao Y Cancer Drug Resist. 2022; 5(2):511-533.

PMID: 35800363 PMC: 9255251. DOI: 10.20517/cdr.2021.145.


Editorial to special issue Frontiers of Data Analysis.

Jin Z, Sun J J Appl Stat. 2022; 48(8):1349-1351.

PMID: 35706465 PMC: 9042080. DOI: 10.1080/02664763.2021.1922853.

References
1.
Sanjiv K, Hagenkort A, Calderon-Montano J, Koolmeister T, Reaper P, Mortusewicz O . Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Rep. 2016; 14(2):298-309. PMC: 4713868. DOI: 10.1016/j.celrep.2015.12.032. View

2.
Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K . A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene. 1997; 15(18):2145-50. DOI: 10.1038/sj.onc.1201542. View

3.
Wagenbach M, Vicente J, Ovechkina Y, Domnitz S, Wordeman L . Functional characterization of MCAK/Kif2C cancer mutations using high-throughput microscopic analysis. Mol Biol Cell. 2019; 31(7):580-588. PMC: 7202071. DOI: 10.1091/mbc.E19-09-0503. View

4.
Quail D, Bowman R, Akkari L, Quick M, Schuhmacher A, Huse J . The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016; 352(6288):aad3018. PMC: 5450629. DOI: 10.1126/science.aad3018. View

5.
Chen Y, Sullivan C, Peng C, Shan Y, Hu Y, Li D . A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood. 2011; 118(2):390-400. PMC: 3138690. DOI: 10.1182/blood-2010-11-316760. View